Drugs / ethynyluracil
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001579 | Jun 1997 → Mar 2001 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004901 | Oct 1999 → Jul 2004 | head and neck cancer | Robert H. Lurie Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00003254 | Apr 1998 → Nov 2002 | colorectal cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ethynyluracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004901 ↗ |
| Route | Oral | “Ethynyluracil and leucovorin calcium are given bid orally on days 1-3 of each week.” NCT00001579 ↗ |